These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34398007)

  • 1. Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis.
    Wang Z; Huang M; Yu B; Huang Y; Zheng S; Yang X; Ning H
    Medicine (Baltimore); 2021 Jul; 100(29):e26524. PubMed ID: 34398007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Shrestha S; Zhao J; Yang C; Zhang J
    Clin Rheumatol; 2020 Jul; 39(7):2139-2150. PubMed ID: 32076916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
    Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
    RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic cytokine measurements: their role in monitoring the response to therapy in patients with rheumatoid arthritis.
    Luqmani R; Sheeran T; Robinson M; Richardson K; Winkles J; Emery P
    Clin Exp Rheumatol; 1994; 12(5):503-8. PubMed ID: 7842530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis.
    Castrejón I; Gibson KA; Pincus T
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S20-8. PubMed ID: 24219037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Efficacy of Acupuncture-Related Therapy in the Treatment of Rheumatoid Arthritis: A Network Meta-Analysis of Randomized Controlled Trials.
    Wan R; Fan Y; Zhao A; Xing Y; Huang X; Zhou L; Wang Y
    Front Immunol; 2022; 13():829409. PubMed ID: 35320944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded Table: Some conventional DMARDs for rheumatoid arthritis.
    Med Lett Drugs Ther; 2021 Nov; 63(1637):e185-e186. PubMed ID: 35085211
    [No Abstract]   [Full Text] [Related]  

  • 10. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
    Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.
    Zhang W; Shi Q; Zhao LD; Li Y; Tang FL; Zhang FC; Zhang X
    J Clin Rheumatol; 2010 Dec; 16(8):375-8. PubMed ID: 21085018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.
    Donahue KE; Gartlehner G; Jonas DE; Lux LJ; Thieda P; Jonas BL; Hansen RA; Morgan LC; Lohr KN
    Ann Intern Med; 2008 Jan; 148(2):124-34. PubMed ID: 18025440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
    Hashimoto T; Yoshida K; Hashimoto N; Nakai A; Kaneshiro K; Suzuki K; Kawasaki Y; Shibanuma N; Hashiramoto A
    Int J Rheum Dis; 2017 Jun; 20(6):722-730. PubMed ID: 27943573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erosion healing in rheumatoid arthritis after anakinra treatment.
    Rau R; Sander O; Wassenberg S
    Ann Rheum Dis; 2003 Jul; 62(7):671-3. PubMed ID: 12810433
    [No Abstract]   [Full Text] [Related]  

  • 15. 2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews.
    Nash P
    Ann Rheum Dis; 2020 Jun; 79(6):679-680. PubMed ID: 32033940
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [DMARDs (disease-modifying antirheumatic drugs)].
    Tanaka E; Yamanaka H
    Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
    Maneiro JR; Souto A; Gomez-Reino JJ
    Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.
    Takamura A; Hirata S; Nagasawa H; Kameda H; Seto Y; Atsumi T; Dohi M; Koike T; Miyasaka N; Harigai M
    Mod Rheumatol; 2013 Mar; 23(2):297-303. PubMed ID: 22572888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.